Trial
NCT05207709
Ribociclib vs. Palbociclib in Patients With Advanced Breast Cancer Within the HER2-Enriched Intrinsic Subtype
Phase IIITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
SOLTI Breast Cancer Research Group
Collaborators
Novartis; Alliance Foundation Trials, LLC.
Condition
Metastatic Breast Cancer
Intervention
Ribociclib + Letrozole OR Fulvestrant
Why stopped
The study was prematurely halted because enrollment was significantly delayed compared with the original projections due to the evolving therapeutic landscape.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-06-25